These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 37063900)

  • 1. Exosomes, MDSCs and Tregs: A new frontier for GVHD prevention and treatment.
    Hess NJ; Kink JA; Hematti P
    Front Immunol; 2023; 14():1143381. PubMed ID: 37063900
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Umbilical cord blood-derived mesenchymal stromal cells promote myeloid-derived suppressor cell proliferation by secreting HLA-G to reduce acute graft-versus-host disease after hematopoietic stem cell transplantation.
    Yang S; Wei Y; Sun R; Lu W; Lv H; Xiao X; Cao Y; Jin X; Zhao M
    Cytotherapy; 2020 Dec; 22(12):718-733. PubMed ID: 32811747
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Early myeloid-derived suppressor cells (HLA-DR
    Wang K; Lv M; Chang YJ; Zhao XY; Zhao XS; Zhang YY; Sun YQ; Wang ZD; Suo P; Zhou Y; Liu D; Zhai SZ; Hong Y; Wang Y; Zhang XH; Xu LP; Liu KY; Huang XJ
    J Hematol Oncol; 2019 Mar; 12(1):31. PubMed ID: 30885244
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Myeloid-Derived Suppressor Cells in the Context of Allogeneic Hematopoietic Stem Cell Transplantation.
    D'Aveni M; Notarantonio AB; Bertrand A; Boulangé L; Pochon C; Rubio MT
    Front Immunol; 2020; 11():989. PubMed ID: 32528476
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Early Recovery of Myeloid-Derived Suppressor Cells After Allogeneic Hematopoietic Transplant: Comparison of Post-Transplantation Cyclophosphamide to Standard Graft-Versus-Host Disease Prophylaxis.
    Oshrine B; Innamarato P; Branthoover H; Nagle L; Verdugo P; Pilon-Thomas S; Beatty M
    Transplant Cell Ther; 2022 Apr; 28(4):203.e1-203.e7. PubMed ID: 34995816
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The mechanistic study behind suppression of GVHD while retaining GVL activities by myeloid-derived suppressor cells.
    Zhang J; Chen HM; Ma G; Zhou Z; Raulet D; Rivera AL; Chen SH; Pan PY
    Leukemia; 2019 Aug; 33(8):2078-2089. PubMed ID: 30737483
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Graft-Versus-Host Disease Prevention by
    Scheurer J; Kitt K; Huber HJ; Fundel-Clemens K; Pflanz S; Debatin KM; Strauss G
    Front Immunol; 2021; 12():754316. PubMed ID: 34721430
    [TBL] [Abstract][Full Text] [Related]  

  • 8. International Society for Cell & Gene Therapy Stem Cell Engineering Committee: Cellular therapies for the treatment of graft-versus-host-disease after hematopoietic stem cell transplant.
    Garcia-Rosa M; Abraham A; Bertaina A; Bhoopalan SV; Bonfim C; Cohen S; DeZern A; Louis C; Oved J; Pavel-Dinu M; Purtill D; Ruggeri A; Russell A; Sharma A; Wynn R; Boelens JJ; Prockop S
    Cytotherapy; 2023 Jun; 25(6):578-589. PubMed ID: 36941149
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Posttransplantation cyclophosphamide expands functional myeloid-derived suppressor cells and indirectly influences Tregs.
    Fletcher RE; Nunes NS; Patterson MT; Vinod N; Khan SM; Mendu SK; Li X; de Paula Pohl A; Wachsmuth LP; Choo-Wosoba H; Eckhaus MA; Venzon DJ; Kanakry CG
    Blood Adv; 2023 Apr; 7(7):1117-1129. PubMed ID: 36595377
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Control of GVHD by regulatory T cells depends on TNF produced by T cells and TNFR2 expressed by regulatory T cells.
    Leclerc M; Naserian S; Pilon C; Thiolat A; Martin GH; Pouchy C; Dominique C; Belkacemi Y; Charlotte F; Maury S; Salomon BL; Cohen JL
    Blood; 2016 Sep; 128(12):1651-9. PubMed ID: 27506541
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of myeloid-derived suppressor cells in allogeneic hematopoietic cell transplantation.
    Koehn BH; Blazar BR
    J Leukoc Biol; 2017 Aug; 102(2):335-341. PubMed ID: 28148718
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Superior GVHD-free, relapse-free survival for G-BM to G-PBSC grafts is associated with higher MDSCs content in allografting for patients with acute leukemia.
    Fan Q; Liu H; Liang X; Yang T; Fan Z; Huang F; Ling Y; Liao X; Xuan L; Xu N; Xu X; Ye J; Liu Q
    J Hematol Oncol; 2017 Jul; 10(1):135. PubMed ID: 28676100
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Role of Myeloid-Derived Suppressor Cells (MDSCs) in Graft-versus-Host Disease (GVHD).
    Demosthenous C; Sakellari I; Douka V; Papayanni PG; Anagnostopoulos A; Gavriilaki E
    J Clin Med; 2021 May; 10(10):. PubMed ID: 34064671
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
    Petersen SL
    Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mesenchymal stromal cell exosome-enhanced regulatory T-cell production through an antigen-presenting cell-mediated pathway.
    Zhang B; Yeo RWY; Lai RC; Sim EWK; Chin KC; Lim SK
    Cytotherapy; 2018 May; 20(5):687-696. PubMed ID: 29622483
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Can we prevent or treat graft-versus-host disease with cellular-therapy?
    Zahid MF; Lazarus HM; Ringdén O; Barrett JA; Gale RP; Hashmi SK
    Blood Rev; 2020 Sep; 43():100669. PubMed ID: 32089398
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Murine CAR19 Tregs suppress acute graft-versus-host disease and maintain graft-versus-tumor responses.
    Bolivar-Wagers S; Loschi ML; Jin S; Thangavelu G; Larson JH; McDonald-Hyman CS; Aguilar EG; Saha A; Koehn BH; Hefazi M; Osborn MJ; Jensen MC; Wagner JE; Pennell CA; Blazar BR
    JCI Insight; 2022 Sep; 7(17):. PubMed ID: 35917188
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interleukin-27 Enforces Regulatory T Cell Functions to Prevent Graft-versus-Host Disease.
    Le HT; Keslar K; Nguyen QT; Blazar BR; Hamilton BK; Min B
    Front Immunol; 2020; 11():181. PubMed ID: 32117306
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Graft monocytic myeloid-derived suppressor cell content predicts the risk of acute graft-versus-host disease after allogeneic transplantation of granulocyte colony-stimulating factor-mobilized peripheral blood stem cells.
    Vendramin A; Gimondi S; Bermema A; Longoni P; Rizzitano S; Corradini P; Carniti C
    Biol Blood Marrow Transplant; 2014 Dec; 20(12):2049-55. PubMed ID: 25246295
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prevention of acute graft-versus-host disease in adult T-cell leukemia-lymphoma patients who received mogamulizumab before allogeneic hematopoietic cell transplantation.
    Inoue Y; Nishimura N; Murai M; Matsumoto M; Watanabe M; Yamada A; Izaki M; Nosaka K; Matsuoka M
    Int J Hematol; 2022 Mar; 115(3):435-439. PubMed ID: 34705226
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.